Retinal layer thickness is decreased in glaucomatous eyes

Article

The thickness of several different layers of the retina is reduced in eyes with glaucoma

"With this in mind, our research team conducted a study focusing on the role of the macula in glaucoma, analysing the configuration of the retinal layers to isolate any pathologic thinning in glaucomatous eyes and to identify the topographic distribution of any such thinning," he said. The results of the study were presented at the most recent annual congress of the European Association for Vision and Eye Research (EVER), which was held in Nice, France.

For the purposes of this study, the team were specifically interested in the retinal nerve fibre layer (RNFL), the retinal ganglion cell plus inner plexiform layer (RGIPL) and the retina as a whole. The central 5° area of the macula was then also divided into 65 segments for further evaluation.

"The maculae of healthy subjects (n = 112; age range: 20–76 years) were scanned with the Cirrus (Carl Zeiss Meditec, Jena, Germany) high definition optical coherence tomography (HD-OCT) instrument, and the 512 x 128 three-dimensional scans were then subjected to quantitative analysis using Matlab R2009b software (The Mathworks Inc., Cambridge, UK), which was developed by our research team," Dr Holzer added. Matlab R2009b locates and 'locks on' to the fovea to increase the accuracy of the positioning of the HD-OCT, as focusing is difficult for glaucoma patients; once the eye is in the correct position, the software automatically detects retinal layers without any manual correction required, which is unique.

He continued, "Using the thickness data we gathered from these scans of healthy eyes, we built colour-coded thickness maps and a normative database (taking into account the effects of age), against which we compared thickness data gathered from subjects with glaucoma of varying stages (n = 25; age range: 42–79 years)." Patients with pre-existing retinal neuropathy were excluded from the study.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.